LOS ANGELES–(BUSINESS WIRE) – Frank R. Cruz law firm is announcing an investigation on behalf of Fennec Pharmaceuticals Inc. ("Fennec" or "Company") (NASDAQ: FENC) investors into possible violations of the Company's federal securities laws.
If you are a shareholder who has suffered a loss, click here to participate.
On August 11, 2020, Fennec announced that it has received a full response letter ("CRL") regarding the Company's New Drug Application ("NDA") for PEDMARK from the United States Food and Drug Administration ("FDA"), a Formulation of sodium thiosulfate for intravenous administration for the ototoxicity associated with cisplatin chemotherapy. According to the CRL, "after completing a pre-audit of the drug manufacturer's (Fennec) manufacturing facility, the FDA identified deficiencies that resulted in a Form 483, which contains a list of required conditions or practices, prior to PEDMARK's approval being resolved."
In that news, Fennec's share price fell $ 3.51 per share, or 34%, to close at $ 6.66 per share on August 11, 2020, hurting investors.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you have purchased Fennec securities, have information or would like to learn more about these claims, or have any questions about this announcement or your rights or interests in relation to these matters, please contact Frank R. Cruz of the Frank R. Law Firms. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067, 310-914-5007, by email at firstname.lastname@example.org or visit our website at www.frankcruzlaw.com. When inquiring by email, please include your postal address, telephone number and number of shares purchased.
This press release may be viewed as a solicitor advertisement in some jurisdictions under applicable laws and ethical rules.